Ann: RELINT: FPH: Disclosure Senior Managers Relevant Interests

• Release Date: 15/09/15 11:25
• Summary: RELINT: FPH: Disclosure Senior Managers Relevant Interests
• Price Sensitive: No
• Download Document  14.35KB

					FPH
15/09/2015 11:25
RELINT
NOT PRICE SENSITIVE
REL: 1125 HRS Fisher & Paykel Healthcare Corporation Limited

RELINT: FPH: Disclosure Senior Managers Relevant Interests

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  15/09/2015
Date of last disclosure:   23/06/2015

Director or senior manager giving disclosure
Full name(s):  Paul ANDREASSI
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Vice President Quality & Regulatory

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   "Ordinary Shares
"
Nature of the affected relevant interest(s):  "(a) Beneficial Ownership of
Ordinary Shares
(b) Options to acquire Ordinary Shares
(c) Performance Share Rights over Ordinary Shares"
For that relevant interest-
Number held in class before acquisition or disposal:  "(a) 0
(b) 216,500
(c) 41,200 "
Number held in class after acquisition or disposal:  "(a) 85,458
(b) 121,500
(c) 25,200 "
Current registered holder(s):  Paul ANDREASSI
Registered holder(s) once transfers are registered:  Paul ANDREASSI

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
Date of transaction:  "(a) 11/09/2015
(b) 11/09/2015"
Nature of transaction:  "(a) Exercise of 95,000 options under the Company's
Share Option Scheme
(b) Exercise of 16,000 performance share rights under the Company's
Performance Share Rights scheme"
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  "(a)
$532,171
(b) NZ$Nil"
Number of financial products to which the transaction related:  "(a) 65,458
ordinary shares
(b) 16,000 ordinary shares"
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Cerification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  15-Sep-15
Date of last disclosure:   24-Sep-14

Director or senior manager giving disclosure
Full name(s):  Antony George BARCLAY
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  "(a) Beneficial ownership in
Ordinary Shares
(b) Beneficial ownership in Options to acquire ordinary shares
(c) Beneficial ownership in  Performance Share Rights over ordinary shares"
For that relevant interest-
Number held in class before acquisition or disposal:  "(a) 74,000
(b) 281,166
(c) 59,000 "
Number held in class after acquisition or disposal:  "(a) 75,549
(b) 321,166
(c) 56,500 "
Current registered holder(s):  Antony George BARCLAY
Registered holder(s) once transfers are registered:  Antony George BARCLAY

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Four
Details of transactions requiring disclosure-
Date of transaction:  "(a) 31/08/2015
(b) 03/09/2015
(c) 08/09/2015
(d) 08/09/2015"
Nature of transaction:  "(a) Transfer of 1,549 ordinary shares upon vesting
under an employee share scheme
(b) Exercise of 17,000 Performance Share Rights under the Company's
Performance Share Rights Scheme
(c) Issuance of 40,000 Options under the Company's Share Options Scheme
(d) Issuance of 14,500 Performance Share Rights under the Company's
Performanc Share Rights Scheme "
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  "(a)
NZ$Nil
(b) NZ$Nil
(c) NZ$Nil
(d) NZ$Nil"
Number of financial products to which the transaction related:  "(a) 1,549
Ordinary shares
(b) 17,000 ordinary shares
(c) 40,000 options
(d) 14,500 performance share rights"
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:

Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
Note: Ordinary Shares held by Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited (of which Antony George Barclay is a director) will
no longer be disclosed following the determination by the Company that such
holding does not constitute a relevant interest for Antony George Barclay.

For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Cerification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  15-Sep-15
Date of last disclosure:   24-Sep-14

Director or senior manager giving disclosure
Full name(s):  Paul Nigel SHEARER
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Senior VP Sales & Marketing

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  "(a) Beneficial interest in
Ordinary Shares
(b) Beneficial interest in options to acquire Ordinary Shares
(c) Beneficial Interest in Performance Share Rights over Ordinary Shares"
For that relevant interest-
Number held in class before acquisition or disposal:  "(a) 358,386
(b) 547,000
(c) 81,500"
Number held in class after acquisition or disposal:  "(a) 383,935
(b) 608,000
(c) 79,500"
Current registered holder(s):  Paul Nigel SHEARER
Registered holder(s) once transfers are registered:  Paul Nigel SHEARER

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Four
Details of transactions requiring disclosure-
Date of transaction:  "(a) 31/08/2015
(b) 03/09/2015
(c) 08/09/2015
(d) 08/09/2015"
Nature of transaction:  "(a) Transfer of 1,549 ordinary shares upon vesting
under an employee share scheme
(b) Exercise of 24,000 Performance Share Rights under the Company's
Performance Share Rights Scheme
(c) Issuance of 61,000 Options under the Company's Share Options Scheme
(d) Issuance of 22,000 Performance Share Rights under the Company's
Performanc Share Rights Scheme "
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  "(a)
NZ$Nil
(b) NZ$Nil
(c) NZ$Nil
(d) NZ$Nil"
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:

Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Cerification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.
End CA:00270162 For:FPH    Type:RELINT     Time:2015-09-15 11:25:29